THE UNFINISHED WAR - MICROORGANISMS AGAINST HUMANS SARS-CoV-2 - THE ENEMY FROM NOWHERE

  • E.V. GORDUZA “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Throughout history, humanity was confronted with many epidemics which were generated by different types of microorganisms: parasites, bacteria or viruses. However, in the last two centuries the fight against these invisible enemies has advanced through the implementation of antiseptic measures, vaccines or different medicines (especially antibiotics). In the last hundred years only, a few epidemics were classified as pandemics: the Spanish flu - 1918-1920 (minimum 50 million deaths), the Asian flu - 1957-1959 (2 million deaths), the Hong Kong flu - 1968-1969 (2 million deaths), and HIV - in the last four decades (35 million deaths) (1).

Author Biography

E.V. GORDUZA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Mother and Child Medicine

References

1. Akhter S, Akhtar S. Emerging coronavirus diseases and future perspective. Virus Dis 2020; 31(2): 113-120 / doi.org/10.1007/s13337-020-00590-2.
2. ***World Health Organisation / www.who.int.
3. Yi-Chia W, Ching-Sunga C, Yu-Jiuna C. The outbreak of COVID-19. An overview. J Chi Med Asso 2020; 83(3): 217-220 / doi.org/10.1097/jcma.0000000000000270.
4. Kan B, Wang M, Jing H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 2005; 79: 11892-900 / doi.org/10.1128/jvi.79.18.11892-11900.2005.
5. Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle east respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014; 14(2): 140-145 / doi.org/ 10.1016/s1473-3099(13)70690-x.
6. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control, J Clin Med 2020; 9: 1225 / doi:10.3390/jcm9041225.
7. Mohammadi M, Meskini M, do Nascimento Pinto AL. 2019 Novel coronavirus (COVID-19) over-view. J Public Health (Berl.): From Theory to Practice 2020 /doi.org/10.1007/s10389-020-01258-3.
8. Raskin S. Genetics of COVID-19. Journal de Pediatria 2021; 97(4): 378-386 / doi.org/10.1016/ j.jped. 2020.09.002.
9. Carter-Timofte ME, Jørgensen SE, Freytag MR, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol 2020; 11: 1606 /doi:10.3389/fimmu.2020.01606.
10. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475-481 / doi:10.1016/S2213-2600(20)30079-5.
11. Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incu-bation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact tracing study. J Infect 2020; 80: e1-13 / doi:10.1016/j.jinf.2020.03.006.
12. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019. novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-1069 / doi:10.1001/jama. 2020.1585
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet 2020; 395: 497-506 /doi:10.1016/S0140-6736(20)30183-5.
14. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720 / doi:10.1056/NEJMoa2002032.
15. Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. J Neurol 2020; 267: 1573-1576 /doi:10.1007/s00415-020-09896-z.
16. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033-2040 / doi:10.1182/blood.2020006000.
17. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20: 269-270 / doi:10.1038/s41577-020-0308-3.
18. Tizaoui K, Zidi I, Lee KH, et al. Update of the current knowledge on genetics, evolution, immuno-pathogenesis, and transmission for coronavirus disease 19 (COVID-19). Int J Biol Sci 2020; 16(15): 2906-2923 / doi:10.7150/ijbs.48812.
19. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395: 1607-1608 / doi:10.1016/S0140-6736 (20)31094-1.
20. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Comprehen-sive Clinical Medicine 2020; 2: 874-876 / doi.org/10.1007/s42399-020-00341-w.
21. Hou Y, Zhao J, Martin W, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med 2020; 18(1): 216/doi.org/10.1186/s12916-020-01673-z
22. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical charac-teristics in patients with COVID-19. Clin Chim Acta 2020; 509: 220-223 / doi.org/10.1016/j.cca. 2020.06.026.
23. Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2.J Virol 2020; 94(13): e00510-20 / doi.org/10.1128/JVI.00510-20.
24. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med 2020; NEJMoa2020283 / doi.org/10.1056/NEJMoa2020283.
25. Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics 2020; 14: 40 / doi.org/10.1186/s40246-020-00290-4.
26. Forouzesh M, Rahimi A, Valizadeh R, Dadashzadeh N, Mirzazadeh A. Clinical display, diagnostics and genetic implication of Novel Coronavirus (COVID-19) Epidemic. Eur Rev Medical Pharmacol Sci 2020; 24: 4607-4615 / doi.org/10.26355/eurrev_202004_21047.
27. Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics 2021; 113(1): 1221-1232 / doi:10.1016/j.ygeno.2020.09.059.
28. Lundstrom K. Coronavirus Pandemic-Therapy and Vaccines. Biomedicines 2020; 8(5): 109 / doi:10.3390/biomedicines8050109
29. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics 2020; 52: 549-557 / doi:10.1152/physiolgenomics.00089.2020.
30. Giurgea LT, Han A, Memolo MJ. Universal coronavirus vaccines: the time to start is now. NPJ Vac-cines 2020; 5(1): 43 / doi:10.1038/s41541-020-0198-1.
Published
2021-09-30